Through its leadership position of using these key regulatory proteins, Altor has established the following technologies:

STAR™ (Soluble T-cell Antigen Receptor)/ STAR™ Fusion This unique proprietary STAR™ technology have allowed Altor to produce biologically active, soluble TCR molecules in a single-chain format. Combined with its Fusion technology, Altor is able to produce STAR™ fusion reagents that retain the ability of the TCR to specifically recognize novel targets on virus-infected or cancerous cells, including intracellular antigens that are not accessible to therapeutic antibodies... More on STAR™ Fusion Technology...
	STAR™ Multimers Altor has found that multimeric forms of the STAR™ molecules can be used to evaluate peptide antigen presentation, in the context of MHC molecules, on cancer cells and tissues, and that staining methods employing these reagents have utility in validating and quantifying tumor and viral antigen presentation and in the design and optimization of vaccine-based approaches. As a result, the Company has launched a line of first-in-class research reagents that will allow investigators to gain a better understanding of cancer and viral infection, potentially leading to the development of new diagnostic and therapeutic approaches. In addition, Altor is using STAR™ Multimer staining methods in its clinical development strategy to identify patients most likely to benefit from TCR-based targeted immunotherapy. For technical and order information on research reagents...
STAR-IMPACT™ (Inhibitor of MHC-Peptide Activation of T-cells) Screening Novel TCR and MHC-peptide production techniques have allowed Altor to assemble highly sensitive screening methods to identify compounds that block TCR interaction with the MHC-peptide complex involved in immune disorders. Of particular interest is the isolation of MHC antagonists that inhibit the activity of autoimmune disease-associated HLA molecules, such HLA-DR2 and HLA-DR4. Using these methods, Altor has established proof-of-concept that non-toxic chemical compounds can be isolated that specifically block TCR:HLA-peptide interactions as well as HLA-restricted T-cell responses in vivo. Altor is seeking partnership opportunities for development of these technologies and product candidates. More on STAR-IMPACT™ Technology...
Product Platforms Based on these unique proprietary technologies, Altor has developed the following product platforms: STAR™ Fusion Reagents for diagnosing and targeting cancer and viral infections. STAR™ Multimer Reagents for Research and Design of Anti-Cancer, Anti-Viral Vaccine. More on Product/Clinical Development...

Literature and Publications...